Loading…
Brands International Corporation, a pharmaceutical drug manufacturer in Canada, was cited for Current Good Manufacturing Practice (CGMP) violations and adulteration under federal law. During an FDA inspection in June 2024, investigators documented that the firm limited and delayed the inspection through hostile management behavior, including shoving and shouting at inspectors, and refusing to open drug stability chambers. The company's non-conformance with required manufacturing, processing, packing, and holding controls rendered their drug products adulterated, constituting violations of both sections 501(a)(2)(B) and 501(j) of the Federal Food, Drug, and Cosmetic Act.